Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation

被引：0
|
作者：
Cho, B. C. [1 ]
Shen, Y. [2 ]
Li, Z. [3 ]
Lu, S. [3 ]
Lee, M. A. [4 ]
Song, Z. [5 ]
Park, J. J. W. [6 ]
Lim, S. M. [1 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [2 ,10 ]
Liu, A. [11 ]
Chen, C. [2 ]
Liu, Y. [2 ]
Rui, H. [2 ]
Chen, J. Q. [2 ]
Wang, A. H. [2 ]
Zhang, J. [2 ,10 ]
Mok, T. S. K. [12 ]
机构：
[1] Yonsei Univ, ABMRC, Med Oncol Dept 501, Seoul, South Korea
[2] D3 Bio Wuxi Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Internal Med Dept, Catholic Med Ctr, Seoul, South Korea
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Clin Trials Dept, Hangzhou, Peoples R China
[6] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept Level 1, Sydney, NSW, Australia
[7] Beijing Canc Hosp, Dept Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Szalmuk Family Dept Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, Gastroenterol Dept, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Oncol Dept, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Prince Wales Hosp, Clin Oncol Dept, Li Ka Shing Specialist Clin, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
640P
引用
收藏
页码：S1642 / S1643
页数：2
相关论文
共 50 条
  • [31] Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
    Fakih, Marwan
    Durm, Greg Andrew
    Govindan, Ramaswamy
    Falchook, Gerald Steven
    Soman, Neelesh
    Henary, Haby Adel
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation.
    Price, Timothy
    Grewal, Jaspreet
    Abed, Afaf
    Moore, Melissa
    Yeh, Yu-Min
    Gadgeel, Shirish
    Richardson, Gary
    Underhill, Craig
    Ganju, Vinod
    Lee, Keun-Wook
    Huh, Seok Jae
    Kim, Sang-We
    Yang, Chih-Hsin
    Chen, Yuh-Min
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Millward, Michael
    CANCER RESEARCH, 2022, 82 (12)
  • [33] First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
    Bedard, Philippe L.
    Davies, Michael A.
    Kopetz, Scott
    Flaherty, Keith T.
    Shapiro, Geoffrey
    Luke, Jason John
    Spreafico, Anna
    Wu, Bin
    Gomez, Corinne
    Cartot-Cotton, Sylvaine
    Mazuir, Florent
    Micallef, Sandrine
    Demers, Brigitte
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
    Munster, Pamela
    Aggarwal, Rahul
    Hong, David
    Schellens, Jan H. M.
    van der Noll, Ruud
    Specht, Jennifer
    Witteveen, Petronella O.
    Werner, Theresa L.
    Dees, E. Claire
    Bergsland, Emily
    Agarwal, Neeraj
    Kleha, Joseph F.
    Durante, Michael
    Adams, Laurel
    Smith, Deborah A.
    Lampkin, Thomas A.
    Morris, Shannon R.
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1932 - 1939
  • [35] First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor.
    Li, Jin
    Guo, Ye
    Xue, Junli
    Wu, Wenqiang
    Chen, Shikui
    Tang, Yanan
    Xu, Xiongbin
    Li, Gang
    Hu, Lihong
    Lin, Yunfei
    Shen, Liang
    Xia, Yuanfeng
    Chan, Chi-Chung
    Wang, Zhouchong
    Ni, Dawen
    Ding, Charles
    Chen, Shuhui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
    Falchook, Gerald S.
    Hong, David S.
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Granda, J. Gabrielle
    Zheng, HongXia
    Klevesath, Manfred B.
    Koehler, Karola
    Bladt, Friedhelm
    Johne, Andreas
    Kurzrock, Razelle
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
    Tolcher, Anthony W.
    Park, Wungki
    Wang, Judy S.
    Spira, Alexander I.
    Janne, Pasi A.
    Lee, Ho-Jin
    Gill, Stanley
    LoRusso, Patricia
    Herzberg, Benjamin
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Berlin, Jordan
    Kasi, Anup
    Fujii, Hisaki
    Pelster, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS764 - TPS764
  • [38] First-in-human phase I trial investigating the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients (pts) with advanced solid tumors
    Falchook, G. S.
    Hong, D. S.
    Amin, H. M.
    Fu, S.
    Piha-Paul, S. A.
    Janku, F.
    Klevesath, M. B.
    Koehler, K.
    Johne, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S190 - S190
  • [39] A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6K in advanced solid tumor patients
    Bidyasar, S.
    Kurzrock, R.
    Falchook, G. S.
    Naing, A.
    Wheler, J. J.
    Durand, J.
    Yang, P.
    Johansen, M. J.
    Newman, R. A.
    Khan, R.
    Hong, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study
    Hu, X.
    Zheng, X.
    Mo, H.
    Cui, X.
    Ding, L.
    Tan, F.
    Hu, P.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2018, 29
12345